Collectively, these results fully support our clinical hypothesis that LIMA1 expression at the time of diagnosis of HNSCC can be used for identification of patients who benefit from cancer surgery, from those who tend to develop metastases and whose cancer treatment requires more extensive adjuvant oncological therapies. The gene discussed is LIMA1; the disease is head and neck squamous cell carcinoma.